- Home
- IRON vs SAM Comparison
IRON vs SAM Comparison
Compare IRON & SAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- SAM
- Stock Information
- Founded
- IRON 2017
- SAM 1984
- Country
- IRON United States
- SAM United States
- Employees
- IRON N/A
- SAM N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- SAM Beverages (Production/Distribution)
- Sector
- IRON Health Care
- SAM Consumer Staples
- Exchange
- IRON Nasdaq
- SAM Nasdaq
- Market Cap
- IRON 2.0B
- SAM 2.4B
- IPO Year
- IRON N/A
- SAM 1995
- Fundamental
- Price
- IRON $60.35
- SAM $223.66
- Analyst Decision
- IRON Strong Buy
- SAM Hold
- Analyst Count
- IRON 11
- SAM 10
- Target Price
- IRON $95.73
- SAM $254.89
- AVG Volume (30 Days)
- IRON 325.5K
- SAM 259.5K
- Earning Date
- IRON 08-07-2025
- SAM 07-24-2025
- Dividend Yield
- IRON N/A
- SAM N/A
- EPS Growth
- IRON N/A
- SAM N/A
- EPS
- IRON N/A
- SAM 6.99
- Revenue
- IRON N/A
- SAM $2,049,593,000.00
- Revenue This Year
- IRON N/A
- SAM N/A
- Revenue Next Year
- IRON N/A
- SAM $1.46
- P/E Ratio
- IRON N/A
- SAM $32.00
- Revenue Growth
- IRON N/A
- SAM 2.46
- 52 Week Low
- IRON $30.82
- SAM $185.34
- 52 Week High
- IRON $68.73
- SAM $329.55
- Technical
- Relative Strength Index (RSI)
- IRON 57.22
- SAM 58.46
- Support Level
- IRON $57.54
- SAM $214.30
- Resistance Level
- IRON $64.83
- SAM $225.11
- Average True Range (ATR)
- IRON 2.14
- SAM 5.75
- MACD
- IRON -0.19
- SAM 0.04
- Stochastic Oscillator
- IRON 46.60
- SAM 87.46
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About SAM Boston Beer Company Inc. (The)
Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.